Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Merrion and Novo Nordisk team on oral GLP-1 receptor agonists
February 2009
SHARING OPTIONS:

DUBLIN, Ireland—Merrion Pharmaceuticals and Novo Nordisk A/S have entered into a development and license agreement to for oral formulations of a Novo Nordisk proprietary GLP-1 receptor agonist, using Merrion's proprietary GIPET technology. This is the second license agreement between the two companies concerning Merrion's GIPET technology, the first being an agreement for the development of oral insulin analogues signed in November 2008. Under thus new license agreement, Merrion will receive up to $58 million for the first product developed under the agreement to reach the market based on achievement of certain development, regulatory and sales milestones as well as royalties on sales. Novo Nordisk is responsible and will pay for the development and commercialization of the product candidates. Merrion is responsible for the development and manufacture of the initial clinical batches, with the work overseen by a joint development committee. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.